Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.41)
# 791
Out of 4,810 analysts
100
Total ratings
50.88%
Success rate
1.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $59.67 | +50.83% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $495.83 | -3.19% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $51.34 | +7.13% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $106.50 | -24.88% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $6.99 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $571.06 | +77.74% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $293.92 | +37.79% | 2 | Oct 22, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Neutral | $220 | $240.01 | -8.34% | 23 | Oct 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Reiterates: Overweight | $10 | $7.73 | +29.37% | 5 | Sep 16, 2024 | |
| MNKD MannKind | Reiterates: Overweight | $6.5 | $4.63 | +40.39% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $38.81 | +85.52% | 1 | Apr 13, 2023 |
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $59.67
Upside: +50.83%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $495.83
Upside: -3.19%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $51.34
Upside: +7.13%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $106.50
Upside: -24.88%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $6.99
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $571.06
Upside: +77.74%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $293.92
Upside: +37.79%
Alnylam Pharmaceuticals
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $240.01
Upside: -8.34%
Aurinia Pharmaceuticals
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $7.73
Upside: +29.37%
MannKind
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $4.63
Upside: +40.39%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $38.81
Upside: +85.52%